- Home
- NVAX vs ZD Comparison
NVAX vs ZD Comparison
Compare NVAX & ZD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- ZD
- Stock Information
- Founded
- NVAX 1987
- ZD 1995
- Country
- NVAX United States
- ZD United States
- Employees
- NVAX N/A
- ZD N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- ZD Advertising
- Sector
- NVAX Health Care
- ZD Consumer Discretionary
- Exchange
- NVAX Nasdaq
- ZD Nasdaq
- Market Cap
- NVAX 2.0B
- ZD N/A
- IPO Year
- NVAX 1995
- ZD 1999
- Fundamental
- Price
- NVAX $8.57
- ZD $54.78
- Analyst Decision
- NVAX Buy
- ZD Buy
- Analyst Count
- NVAX 6
- ZD 8
- Target Price
- NVAX $17.83
- ZD $70.50
- AVG Volume (30 Days)
- NVAX 3.3M
- ZD 474.0K
- Earning Date
- NVAX 02-26-2025
- ZD 02-19-2025
- Dividend Yield
- NVAX N/A
- ZD N/A
- EPS Growth
- NVAX N/A
- ZD 41.38
- EPS
- NVAX N/A
- ZD 1.38
- Revenue
- NVAX $885,193,000.00
- ZD $1,378,750,000.00
- Revenue This Year
- NVAX N/A
- ZD $6.74
- Revenue Next Year
- NVAX N/A
- ZD $5.56
- P/E Ratio
- NVAX N/A
- ZD $39.75
- Revenue Growth
- NVAX N/A
- ZD 0.58
- 52 Week Low
- NVAX $3.53
- ZD $37.76
- 52 Week High
- NVAX $23.86
- ZD $70.90
- Technical
- Relative Strength Index (RSI)
- NVAX 48.28
- ZD 43.15
- Support Level
- NVAX $7.62
- ZD $53.62
- Resistance Level
- NVAX $8.67
- ZD $56.97
- Average True Range (ATR)
- NVAX 0.46
- ZD 1.87
- MACD
- NVAX -0.03
- ZD -0.55
- Stochastic Oscillator
- NVAX 44.60
- ZD 18.53
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.